Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMivacurium
Identification
- Name
- Mivacurium
- Accession Number
- DB01226 (APRD01119)
- Type
- Small Molecule
- Groups
- Approved
- Description
Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.
- Structure
Structure for DB01226 (Mivacurium)
- Synonyms
- Mivacurium
- Product Ingredients
Ingredient UNII CAS InChI Key Mivacurium chloride 600ZG213C3 106861-44-3 WMSYWJSZGVOIJW-ONUALHDOSA-L - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Mivacron Liquid 2 mg Intravenous Abbvie 1994-12-31 2012-11-03 Canada 
Mivacron Solution 2 mg/mL Intravenous Abbvie 2015-01-30 Not applicable US 
- Categories
- Anticholinergic Agents
- Central Nervous System Depressants
- Muscarinic Antagonists
- Muscle Relaxants
- Muscle Relaxants, Peripherally Acting Agents
- Musculo-Skeletal System
- Neuromuscular Agents
- Neuromuscular Blocking Agents
- Neuromuscular-Blocking Agents (Nondepolarizing)
- Nicotinic Antagonists
- Peripheral Nervous System Agents
- UNII
- 77D66S9Q93
- CAS number
- 133814-19-4
- Weight
- Average: 1029.2608
Monoisotopic: 1028.560955278 - Chemical Formula
- C58H80N2O14
- InChI Key
- ILVYCEVXHALBSC-OTBYEXOQSA-N
- InChI
- InChI=1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2/b14-13+/t45-,46-,59?,60?/m1/s1
- IUPAC Name
- (1R)-2-(3-{[(4E)-8-{3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propoxy}-8-oxooct-4-enoyl]oxy}propyl)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium
- SMILES
- COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC
Pharmacology
- Indication
For inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
- Associated Therapies
- Pharmacodynamics
Mivacurium is a short-acting, nondepolarizing skeletal neuromuscular blocking agent which is hydrolyzed by plasma cholinesterase. Mivacurium results in a blockade of neuromuscular transmission by binding competitively with cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine. The neuromuscular block produced by mivacurium is readily antagonized by anticholinesterase agents. The deeper the level of neuromuscular block at reversal, the longer the time required for recovery of neuromuscular function and the greater the dose of anticholinesterase agent required. Because spontaneous recovery after mivacurium is rapid, routine reversal may not always result in a clinical benefit.
- Mechanism of action
Mivacurium binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.
Target Actions Organism ANeuronal acetylcholine receptor subunit alpha-2 antagonistHuman NMuscarinic acetylcholine receptor M2 antagonistpartial agonistHuman NMuscarinic acetylcholine receptor M3 antagonistHuman UCholinesterase Not Available Human - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
The protein binding of mivacurium has not been determined due to its rapid hydrolysis by plasma cholinesterase.
- Metabolism
Extensive and rapid via enzymatic hydrolysis catalyzed by plasma cholinesterase. Biotransformation may be significantly slowed in patients with abnormal or decreased plasma cholinesterase activity, especially individuals with a homozygous atypical cholinesterase gene abnormality.
- Route of elimination
- Not Available
- Half life
The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.
- Clearance
- Not Available
- Toxicity
Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 1,10-Phenanthroline 1,10-Phenanthroline may decrease the neuromuscular blocking activities of Mivacurium. Experimental 16-Bromoepiandrosterone Mivacurium may increase the adverse neuromuscular activities of 16-Bromoepiandrosterone. Investigational 19-norandrostenedione Mivacurium may increase the adverse neuromuscular activities of 19-norandrostenedione. Experimental, Illicit 5-androstenedione Mivacurium may increase the adverse neuromuscular activities of 5-androstenedione. Experimental, Illicit Acetyldigitoxin Mivacurium may increase the arrhythmogenic activities of Acetyldigitoxin. Approved Acetyldigoxin Mivacurium may increase the arrhythmogenic activities of Acetyldigoxin. Experimental Agmatine Agmatine may increase the neuromuscular blocking activities of Mivacurium. Experimental, Investigational Alclometasone Mivacurium may increase the adverse neuromuscular activities of Alclometasone. Approved Aldosterone Mivacurium may increase the adverse neuromuscular activities of Aldosterone. Experimental, Investigational Ambenonium Ambenonium may decrease the neuromuscular blocking activities of Mivacurium. Approved Amcinonide Mivacurium may increase the adverse neuromuscular activities of Amcinonide. Approved Amikacin The therapeutic efficacy of Mivacurium can be increased when used in combination with Amikacin. Approved, Investigational, Vet Approved Amiodarone Amiodarone may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Amlodipine Amlodipine may increase the neuromuscular blocking activities of Mivacurium. Approved Androstenedione Mivacurium may increase the adverse neuromuscular activities of Androstenedione. Experimental, Illicit Anecortave Mivacurium may increase the adverse neuromuscular activities of Anecortave. Investigational anecortave acetate Mivacurium may increase the adverse neuromuscular activities of anecortave acetate. Investigational Apramycin Apramycin may increase the respiratory depressant activities of Mivacurium. Experimental, Vet Approved Aranidipine Aranidipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Arbekacin Arbekacin may increase the respiratory depressant activities of Mivacurium. Approved, Investigational Atamestane Mivacurium may increase the adverse neuromuscular activities of Atamestane. Investigational Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Mivacurium. Approved, Vet Approved Azelnidipine Azelnidipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Azosemide Azosemide may decrease the neuromuscular blocking activities of Mivacurium. Investigational Barnidipine Barnidipine may increase the neuromuscular blocking activities of Mivacurium. Approved Beclomethasone dipropionate The risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Beclomethasone dipropionate. Approved, Investigational Bekanamycin Bekanamycin may increase the respiratory depressant activities of Mivacurium. Experimental Bencyclane Bencyclane may increase the neuromuscular blocking activities of Mivacurium. Experimental Benidipine Benidipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Mivacurium. Approved Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Mivacurium. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Mivacurium. Approved Bepridil Bepridil may increase the neuromuscular blocking activities of Mivacurium. Approved, Withdrawn Betamethasone Mivacurium may increase the adverse neuromuscular activities of Betamethasone. Approved, Vet Approved Bioallethrin Bioallethrin may increase the neuromuscular blocking activities of Mivacurium. Approved, Experimental Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Mivacurium. Approved Botulinum Toxin Type A Botulinum Toxin Type A may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Botulinum Toxin Type B Mivacurium may increase the neuromuscular blocking activities of Botulinum Toxin Type B. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Mivacurium. Approved Budesonide The risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Budesonide. Approved Bumetanide Bumetanide may decrease the neuromuscular blocking activities of Mivacurium. Approved Bupropion The risk or severity of adverse effects can be increased when Bupropion is combined with Mivacurium. Approved Capreomycin Capreomycin may increase the neuromuscular blocking activities of Mivacurium. Approved Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Mivacurium. Approved, Investigational Carboxyamidotriazole Carboxyamidotriazole may increase the neuromuscular blocking activities of Mivacurium. Investigational Caroverine Caroverine may increase the neuromuscular blocking activities of Mivacurium. Experimental Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Mivacurium. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mivacurium. Approved Chlortetracycline Chlortetracycline may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Vet Approved Chlorthalidone Chlorthalidone may decrease the neuromuscular blocking activities of Mivacurium. Approved Ciclesonide Mivacurium may increase the adverse neuromuscular activities of Ciclesonide. Approved, Investigational Cilnidipine Cilnidipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Cinnarizine Cinnarizine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Clemastine The risk or severity of adverse effects can be increased when Clemastine is combined with Mivacurium. Approved, Investigational Clevidipine Clevidipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Clindamycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Clindamycin. Approved, Vet Approved Clobetasol Mivacurium may increase the adverse neuromuscular activities of Clobetasol. Approved, Investigational Clobetasol propionate Mivacurium may increase the adverse neuromuscular activities of Clobetasol propionate. Approved Clobetasone Mivacurium may increase the adverse neuromuscular activities of Clobetasone. Approved Clocortolone Mivacurium may increase the adverse neuromuscular activities of Clocortolone. Approved Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Mivacurium. Approved, Illicit Colistimethate Colistimethate may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Cortexolone 17α-propionate Mivacurium may increase the adverse neuromuscular activities of Cortexolone 17α-propionate. Investigational Corticosterone Mivacurium may increase the adverse neuromuscular activities of Corticosterone. Experimental Cortisone acetate Mivacurium may increase the adverse neuromuscular activities of Cortisone acetate. Approved, Investigational Coumaphos Coumaphos may decrease the neuromuscular blocking activities of Mivacurium. Vet Approved Cyclandelate Cyclandelate may increase the neuromuscular blocking activities of Mivacurium. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mivacurium. Approved Cyclosporine The therapeutic efficacy of Mivacurium can be increased when used in combination with Cyclosporine. Approved, Investigational, Vet Approved Cymarin Mivacurium may increase the arrhythmogenic activities of Cymarin. Experimental Darodipine Darodipine may increase the neuromuscular blocking activities of Mivacurium. Experimental Decamethonium Decamethonium may decrease the neuromuscular blocking activities of Mivacurium. Approved Deflazacort Mivacurium may increase the adverse neuromuscular activities of Deflazacort. Approved, Investigational Demecarium Demecarium may decrease the neuromuscular blocking activities of Mivacurium. Approved Demeclocycline Demeclocycline may increase the neuromuscular blocking activities of Mivacurium. Approved Desflurane Desflurane may increase the neuromuscular blocking activities of Mivacurium. Approved Deslanoside Mivacurium may increase the arrhythmogenic activities of Deslanoside. Approved Desonide Mivacurium may increase the adverse neuromuscular activities of Desonide. Approved, Investigational Desoximetasone Mivacurium may increase the adverse neuromuscular activities of Desoximetasone. Approved Desoxycorticosterone acetate Mivacurium may increase the adverse neuromuscular activities of Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate Mivacurium may increase the adverse neuromuscular activities of Desoxycorticosterone Pivalate. Experimental, Vet Approved Desvenlafaxine The risk or severity of adverse effects can be increased when Mivacurium is combined with Desvenlafaxine. Approved, Investigational Dexamethasone The risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Dexamethasone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate Mivacurium may increase the adverse neuromuscular activities of Dexamethasone isonicotinate. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mivacurium. Approved Dexniguldipine Dexniguldipine may increase the neuromuscular blocking activities of Mivacurium. Experimental Dextromethorphan The risk or severity of adverse effects can be increased when Mivacurium is combined with Dextromethorphan. Approved Dexverapamil Dexverapamil may increase the neuromuscular blocking activities of Mivacurium. Experimental Dibekacin Dibekacin may increase the respiratory depressant activities of Mivacurium. Experimental Dichlorvos Dichlorvos may decrease the neuromuscular blocking activities of Mivacurium. Vet Approved Diethyl ether Diethyl ether may increase the neuromuscular blocking activities of Mivacurium. Experimental Diflorasone Mivacurium may increase the adverse neuromuscular activities of Diflorasone. Approved Difluocortolone Mivacurium may increase the adverse neuromuscular activities of Difluocortolone. Approved, Investigational, Withdrawn Difluprednate Mivacurium may increase the adverse neuromuscular activities of Difluprednate. Approved Digitoxin Mivacurium may increase the arrhythmogenic activities of Digitoxin. Approved, Investigational Digoxin Mivacurium may increase the arrhythmogenic activities of Digoxin. Approved Digoxin Immune Fab (Ovine) Mivacurium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine). Approved Dihydrostreptomycin Dihydrostreptomycin may increase the respiratory depressant activities of Mivacurium. Investigational, Vet Approved Diltiazem Diltiazem may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mivacurium. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mivacurium. Approved, Investigational Dipivefrin Dipivefrin may decrease the neuromuscular blocking activities of Mivacurium. Approved Distigmine Distigmine may decrease the neuromuscular blocking activities of Mivacurium. Experimental Docusate The therapeutic efficacy of Docusate can be decreased when used in combination with Mivacurium. Approved Donepezil Donepezil may decrease the neuromuscular blocking activities of Mivacurium. Approved Dotarizine Dotarizine may increase the neuromuscular blocking activities of Mivacurium. Investigational Doxycycline Doxycycline may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mivacurium. Approved, Vet Approved Echothiophate Echothiophate may decrease the neuromuscular blocking activities of Mivacurium. Approved Edrophonium Edrophonium may decrease the neuromuscular blocking activities of Mivacurium. Approved Efonidipine Efonidipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Emopamil Emopamil may increase the neuromuscular blocking activities of Mivacurium. Experimental Enflurane Enflurane may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Vet Approved Eperisone Eperisone may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Equilenin Mivacurium may increase the adverse neuromuscular activities of Equilenin. Experimental Equilin Mivacurium may increase the adverse neuromuscular activities of Equilin. Approved Estrone Mivacurium may increase the adverse neuromuscular activities of Estrone. Approved Estrone sulfate Mivacurium may increase the adverse neuromuscular activities of Estrone sulfate. Approved Etacrynic acid Etacrynic acid may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Ethanol Mivacurium may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethosuximide Ethosuximide may increase the neuromuscular blocking activities of Mivacurium. Approved Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Mivacurium. Approved Felodipine Felodipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Fendiline Fendiline may increase the neuromuscular blocking activities of Mivacurium. Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Mivacurium. Approved, Illicit, Investigational, Vet Approved Fenthion Fenthion may decrease the neuromuscular blocking activities of Mivacurium. Vet Approved Fish oil Fish oil may increase the neuromuscular blocking activities of Mivacurium. Approved, Nutraceutical Fluasterone Mivacurium may increase the adverse neuromuscular activities of Fluasterone. Investigational Fludrocortisone Mivacurium may increase the adverse neuromuscular activities of Fludrocortisone. Approved, Investigational Flumethasone Mivacurium may increase the adverse neuromuscular activities of Flumethasone. Approved, Vet Approved Flunarizine Flunarizine may increase the neuromuscular blocking activities of Mivacurium. Approved Flunisolide Mivacurium may increase the adverse neuromuscular activities of Flunisolide. Approved, Investigational Fluocinolone Acetonide Mivacurium may increase the adverse neuromuscular activities of Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide Mivacurium may increase the adverse neuromuscular activities of Fluocinonide. Approved, Investigational Fluocortolone Mivacurium may increase the adverse neuromuscular activities of Fluocortolone. Approved, Withdrawn Fluorometholone Mivacurium may increase the adverse neuromuscular activities of Fluorometholone. Approved, Investigational Fluoxetine The risk or severity of adverse effects can be increased when Mivacurium is combined with Fluoxetine. Approved, Vet Approved Fluprednidene Mivacurium may increase the adverse neuromuscular activities of Fluprednidene. Approved, Withdrawn Fluprednisolone Mivacurium may increase the adverse neuromuscular activities of Fluprednisolone. Approved Flurandrenolide Mivacurium may increase the adverse neuromuscular activities of Flurandrenolide. Approved Fluspirilene Fluspirilene may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Fluticasone Mivacurium may increase the adverse neuromuscular activities of Fluticasone. Approved, Experimental, Investigational Fluticasone furoate Mivacurium may increase the adverse neuromuscular activities of Fluticasone furoate. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Mivacurium. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Mivacurium is combined with Fluvoxamine. Approved, Investigational Formestane Mivacurium may increase the adverse neuromuscular activities of Formestane. Approved, Investigational, Withdrawn Fosphenytoin Fosphenytoin may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Framycetin Framycetin may increase the respiratory depressant activities of Mivacurium. Approved Furosemide Furosemide may decrease the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Gabapentin Gabapentin may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Galantamine Galantamine may decrease the neuromuscular blocking activities of Mivacurium. Approved Gallamine Triethiodide Gallamine Triethiodide may decrease the neuromuscular blocking activities of Mivacurium. Approved Gallopamil Gallopamil may increase the neuromuscular blocking activities of Mivacurium. Investigational Geneticin Geneticin may increase the respiratory depressant activities of Mivacurium. Experimental Gentamicin Gentamicin may increase the respiratory depressant activities of Mivacurium. Approved, Vet Approved GENTAMICIN C1A GENTAMICIN C1A may increase the respiratory depressant activities of Mivacurium. Experimental Ginkgo biloba Ginkgo biloba may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Nutraceutical Gitoformate Mivacurium may increase the arrhythmogenic activities of Gitoformate. Experimental Glycerin The therapeutic efficacy of Glycerin can be decreased when used in combination with Mivacurium. Approved, Investigational Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Mivacurium. Approved, Investigational Halcinonide Mivacurium may increase the adverse neuromuscular activities of Halcinonide. Approved, Investigational, Withdrawn Halothane Halothane may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved HE3286 Mivacurium may increase the adverse neuromuscular activities of HE3286. Investigational Huperzine A Huperzine A may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Hydrochlorothiazide The serum concentration of Hydrochlorothiazide can be increased when it is combined with Mivacurium. Approved, Vet Approved Hydrocodone Mivacurium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydrocortisone The risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Hydrocortisone. Approved, Vet Approved Hydrocortisone acetate The risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Hydrocortisone acetate. Approved, Vet Approved Hydrocortisone butyrate The risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Hydrocortisone butyrate. Approved, Vet Approved Hydroflumethiazide Hydroflumethiazide may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mivacurium. Approved Hygromycin B Hygromycin B may increase the respiratory depressant activities of Mivacurium. Vet Approved Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Mivacurium. Approved Ipidacrine Ipidacrine may decrease the neuromuscular blocking activities of Mivacurium. Experimental Ipratropium The risk or severity of adverse effects can be increased when Mivacurium is combined with Ipratropium. Approved Isepamicin Isepamicin may increase the respiratory depressant activities of Mivacurium. Experimental Isoflurane Isoflurane may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Isoflurophate Isoflurophate may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Withdrawn Isradipine Isradipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Istaroxime Mivacurium may increase the adverse neuromuscular activities of Istaroxime. Investigational Kanamycin Kanamycin may increase the respiratory depressant activities of Mivacurium. Approved, Investigational, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Mivacurium. Approved Lacidipine Lacidipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Mivacurium. Approved Lamotrigine Lamotrigine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Lanatoside C Mivacurium may increase the arrhythmogenic activities of Lanatoside C. Experimental Lercanidipine Lercanidipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Levetiracetam Levetiracetam may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Levodopa The risk or severity of adverse effects can be increased when Levodopa is combined with Mivacurium. Approved Lidoflazine Lidoflazine may increase the neuromuscular blocking activities of Mivacurium. Experimental Lincomycin Lincomycin may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Lithium cation Lithium may increase the neuromuscular blocking activities of Mivacurium. Experimental Lomerizine Lomerizine may increase the neuromuscular blocking activities of Mivacurium. Experimental Loperamide Loperamide may increase the neuromuscular blocking activities of Mivacurium. Approved Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Mivacurium. Approved, Investigational Lorpiprazole The therapeutic efficacy of Mivacurium can be increased when used in combination with Lorpiprazole. Approved Loteprednol Mivacurium may increase the adverse neuromuscular activities of Loteprednol. Approved Magnesium carbonate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium carbonate. Approved, Investigational Magnesium citrate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium citrate. Approved Magnesium hydroxide The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium hydroxide. Approved, Investigational Magnesium oxide Magnesium oxide may increase the neuromuscular blocking activities of Mivacurium. Approved Magnesium salicylate Magnesium salicylate may increase the neuromuscular blocking activities of Mivacurium. Approved Magnesium sulfate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium Trisilicate. Approved Malathion Malathion may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Manidipine Manidipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational ME-609 Mivacurium may increase the adverse neuromuscular activities of ME-609. Investigational Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Mivacurium. Approved Medrysone Mivacurium may increase the adverse neuromuscular activities of Medrysone. Approved Mefloquine Mefloquine may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Melengestrol Mivacurium may increase the adverse neuromuscular activities of Melengestrol. Vet Approved Memantine Memantine may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Menthol Menthol may increase the neuromuscular blocking activities of Mivacurium. Approved Methanesulfonyl Fluoride Methanesulfonyl Fluoride may decrease the neuromuscular blocking activities of Mivacurium. Investigational Methoxyflurane Methoxyflurane may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Vet Approved Methsuximide Methsuximide may increase the neuromuscular blocking activities of Mivacurium. Approved Methyclothiazide Methyclothiazide may decrease the neuromuscular blocking activities of Mivacurium. Approved Methylprednisolone The risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Methylprednisolone. Approved, Vet Approved Metildigoxin Mivacurium may increase the arrhythmogenic activities of Metildigoxin. Experimental Metoclopramide The therapeutic efficacy of Mivacurium can be decreased when used in combination with Metoclopramide. Approved, Investigational Mibefradil Mibefradil may increase the neuromuscular blocking activities of Mivacurium. Investigational, Withdrawn Micronomicin Micronomicin may increase the respiratory depressant activities of Mivacurium. Experimental Minaprine Minaprine may decrease the neuromuscular blocking activities of Mivacurium. Approved Mineral oil The therapeutic efficacy of Mineral oil can be decreased when used in combination with Mivacurium. Approved, Vet Approved Minocycline Minocycline may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Mometasone Mivacurium may increase the adverse neuromuscular activities of Mometasone. Approved, Vet Approved Naftopidil Naftopidil may increase the neuromuscular blocking activities of Mivacurium. Investigational NCX 1022 Mivacurium may increase the adverse neuromuscular activities of NCX 1022. Investigational Neamine Neamine may increase the respiratory depressant activities of Mivacurium. Experimental Neomycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Neomycin. Approved, Vet Approved Neostigmine Neostigmine may decrease the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Netilmicin Netilmicin may increase the respiratory depressant activities of Mivacurium. Approved, Investigational Nicardipine Nicardipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Nifedipine Nifedipine may increase the neuromuscular blocking activities of Mivacurium. Approved Niguldipine Niguldipine may increase the neuromuscular blocking activities of Mivacurium. Experimental Niludipine Niludipine may increase the neuromuscular blocking activities of Mivacurium. Experimental Nilvadipine Nilvadipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Nimesulide Nimesulide may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Withdrawn Nimodipine Nimodipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Nisoldipine Nisoldipine may increase the neuromuscular blocking activities of Mivacurium. Approved Nitrendipine Nitrendipine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Nitrous oxide Nitrous oxide may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Nylidrin Nylidrin may increase the neuromuscular blocking activities of Mivacurium. Approved Oleandrin Mivacurium may increase the arrhythmogenic activities of Oleandrin. Experimental, Investigational Oleoyl-estrone Mivacurium may increase the adverse neuromuscular activities of Oleoyl-estrone. Investigational Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Mivacurium. Approved Otilonium Otilonium may increase the neuromuscular blocking activities of Mivacurium. Experimental, Investigational Ouabain Mivacurium may increase the arrhythmogenic activities of Ouabain. Approved Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Mivacurium. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Mivacurium. Approved, Investigational, Vet Approved Oxytetracycline Oxytetracycline may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational, Vet Approved Paramethasone Mivacurium may increase the adverse neuromuscular activities of Paramethasone. Approved Paraoxon Paraoxon may decrease the neuromuscular blocking activities of Mivacurium. Experimental Paromomycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Paromomycin. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Mivacurium is combined with Paroxetine. Approved, Investigational Penfluridol Penfluridol may increase the neuromuscular blocking activities of Mivacurium. Experimental Peruvoside Mivacurium may increase the arrhythmogenic activities of Peruvoside. Experimental Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Mivacurium. Approved, Investigational Phenytoin Phenytoin may decrease the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Physostigmine Physostigmine may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Pinaverium Pinaverium may increase the neuromuscular blocking activities of Mivacurium. Approved Piretanide Piretanide may decrease the neuromuscular blocking activities of Mivacurium. Approved Pirlimycin Pirlimycin may increase the neuromuscular blocking activities of Mivacurium. Vet Approved Plazomicin Plazomicin may increase the respiratory depressant activities of Mivacurium. Approved, Investigational Polymyxin B Sulfate The therapeutic efficacy of Mivacurium can be increased when used in combination with Polymyxin B Sulfate. Approved, Vet Approved Potassium Chloride The risk or severity of gastrointestinal ulceration can be increased when Mivacurium is combined with Potassium Chloride. Approved, Withdrawn Pramipexole Mivacurium may increase the sedative activities of Pramipexole. Approved, Investigational Prasterone Mivacurium may increase the adverse neuromuscular activities of Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate Mivacurium may increase the adverse neuromuscular activities of Prasterone sulfate. Investigational Prednicarbate Mivacurium may increase the adverse neuromuscular activities of Prednicarbate. Approved, Investigational Prednisolone The risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Prednisolone. Approved, Vet Approved Prednisone Mivacurium may increase the adverse neuromuscular activities of Prednisone. Approved, Vet Approved Pregabalin The therapeutic efficacy of Mivacurium can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Pregnenolone Mivacurium may increase the adverse neuromuscular activities of Pregnenolone. Approved, Experimental, Investigational Prenylamine Prenylamine may increase the neuromuscular blocking activities of Mivacurium. Withdrawn Procainamide Procainamide may increase the neuromuscular blocking activities of Mivacurium. Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mivacurium. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Mivacurium. Approved, Investigational Proscillaridin Mivacurium may increase the arrhythmogenic activities of Proscillaridin. Experimental Pseudoephedrine The risk or severity of adverse effects can be increased when Mivacurium is combined with Pseudoephedrine. Approved Puromycin Puromycin may increase the respiratory depressant activities of Mivacurium. Experimental Pyrantel The risk or severity of adverse effects can be increased when Mivacurium is combined with Pyrantel. Approved, Vet Approved Pyridostigmine Pyridostigmine may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Mivacurium. Approved Quinethazone Quinethazone may decrease the neuromuscular blocking activities of Mivacurium. Approved Quinidine Quinidine may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Quinine Quinine may increase the neuromuscular blocking activities of Mivacurium. Approved Ribostamycin Ribostamycin may increase the respiratory depressant activities of Mivacurium. Approved, Investigational Rimexolone Mivacurium may increase the adverse neuromuscular activities of Rimexolone. Approved Rivastigmine Rivastigmine may decrease the neuromuscular blocking activities of Mivacurium. Approved, Investigational Rizatriptan The risk or severity of adverse effects can be increased when Mivacurium is combined with Rizatriptan. Approved Ropinirole Mivacurium may increase the sedative activities of Ropinirole. Approved, Investigational Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Mivacurium. Approved, Investigational Seletracetam Seletracetam may increase the neuromuscular blocking activities of Mivacurium. Investigational Sevoflurane Sevoflurane may increase the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Sisomicin Sisomicin may increase the respiratory depressant activities of Mivacurium. Investigational Sodium phosphate, monobasic The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Mivacurium. Approved Spironolactone Spironolactone may increase the neuromuscular blocking activities of Mivacurium. Approved Streptomycin Streptomycin may increase the respiratory depressant activities of Mivacurium. Approved, Vet Approved Sumatriptan The risk or severity of adverse effects can be increased when Mivacurium is combined with Sumatriptan. Approved, Investigational Tacrine Tacrine may decrease the neuromuscular blocking activities of Mivacurium. Investigational, Withdrawn Terodiline Terodiline may increase the neuromuscular blocking activities of Mivacurium. Experimental Tetracycline The therapeutic efficacy of Mivacurium can be increased when used in combination with Tetracycline. Approved, Vet Approved Tetrahydropalmatine Tetrahydropalmatine may increase the neuromuscular blocking activities of Mivacurium. Investigational Tetrandrine Tetrandrine may increase the neuromuscular blocking activities of Mivacurium. Experimental Tixocortol Mivacurium may increase the adverse neuromuscular activities of Tixocortol. Approved, Withdrawn Tobramycin Tobramycin may increase the respiratory depressant activities of Mivacurium. Approved, Investigational Tolfenamic Acid Tolfenamic Acid may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Mivacurium is combined with Topiramate. Approved Torasemide Torasemide may decrease the neuromuscular blocking activities of Mivacurium. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Mivacurium. Approved, Investigational Tranilast Tranilast may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational Triamcinolone Mivacurium may increase the adverse neuromuscular activities of Triamcinolone. Approved, Vet Approved Trichlorfon Trichlorfon may decrease the neuromuscular blocking activities of Mivacurium. Vet Approved Trichlormethiazide Trichlormethiazide may decrease the neuromuscular blocking activities of Mivacurium. Approved, Vet Approved Trichloroethylene Trichloroethylene may increase the neuromuscular blocking activities of Mivacurium. Approved Trimebutine Trimebutine may increase the neuromuscular blocking activities of Mivacurium. Approved Trimethadione Trimethadione may increase the neuromuscular blocking activities of Mivacurium. Approved Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Mivacurium. Approved Tubocurarine Tubocurarine may decrease the neuromuscular blocking activities of Mivacurium. Approved Tyrothricin Tyrothricin may decrease the neuromuscular blocking activities of Mivacurium. Approved Ulobetasol Mivacurium may increase the adverse neuromuscular activities of Ulobetasol. Approved Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with Mivacurium. Approved, Investigational Vancomycin The therapeutic efficacy of Mivacurium can be increased when used in combination with Vancomycin. Approved Vecuronium The risk or severity of adverse effects can be increased when Vecuronium is combined with Mivacurium. Approved Venlafaxine The risk or severity of adverse effects can be increased when Mivacurium is combined with Venlafaxine. Approved Verapamil Verapamil may increase the neuromuscular blocking activities of Mivacurium. Approved Vinpocetine Vinpocetine may increase the neuromuscular blocking activities of Mivacurium. Investigational WIN 55212-2 The risk or severity of Tachycardia and drowsiness can be increased when Mivacurium is combined with WIN 55212-2. Experimental Xenon Xenon may increase the neuromuscular blocking activities of Mivacurium. Experimental Ziconotide Ziconotide may increase the neuromuscular blocking activities of Mivacurium. Approved Zolmitriptan The risk or severity of adverse effects can be increased when Mivacurium is combined with Zolmitriptan. Approved, Investigational Zolpidem Mivacurium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide Zonisamide may increase the neuromuscular blocking activities of Mivacurium. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Maurizio Francesco Velati, Andrea Busca, Cristina Manfrotto, Marco Nicolini, Claudio Gianluca Pozzoli, "Process for the preparation of mivacurium chloride." U.S. Patent US20070293534, issued December 20, 2007.
US20070293534- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015357
- KEGG Compound
- C07550
- PubChem Compound
- 5281042
- PubChem Substance
- 46505071
- ChemSpider
- 4444509
- ChEBI
- 6958
- ChEMBL
- CHEMBL1182833
- Therapeutic Targets Database
- DAP000716
- PharmGKB
- PA450528
- RxList
- RxList Drug Page
- Wikipedia
- Mivacurium
- ATC Codes
- M03AC10 — Mivacurium chloride
- FDA label
- Download (1.5 MB)
- MSDS
- Download (25.3 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Muscle Relaxation / Sex 1 2 Recruiting Treatment Liver Dysfunction 1 4 Completed Prevention Kidney Diseases / Prostate Hypertrophy 1 4 Completed Treatment Efficacy and Safety of Mivacurium Chloride for Pediatric Patients 1 4 Completed Treatment Intubations / Newborns / Preterms 1 Not Available Completed Not Available Neuromuscular Blockade 1 Not Available Completed Treatment Intubating Conditions / Performance With Respiratory Exercise Device / Postoperative Myalgia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Liquid Intravenous 2 mg Solution Intravenous 2 mg/mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 3.26e-05 mg/mL ALOGPS logP 3.8 ALOGPS logP -0.76 ChemAxon logS -7.5 ALOGPS pKa (Strongest Acidic) 18.59 ChemAxon pKa (Strongest Basic) -4.1 ChemAxon Physiological Charge 2 ChemAxon Hydrogen Acceptor Count 12 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 144.9 Å2 ChemAxon Rotatable Bond Count 30 ChemAxon Refractivity 308.74 m3·mol-1 ChemAxon Polarizability 116.68 Å3 ChemAxon Number of Rings 6 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption - 0.9832 Blood Brain Barrier + 0.9465 Caco-2 permeable + 0.629 P-glycoprotein substrate Substrate 0.8476 P-glycoprotein inhibitor I Non-inhibitor 0.5119 P-glycoprotein inhibitor II Inhibitor 0.7645 Renal organic cation transporter Non-inhibitor 0.5515 CYP450 2C9 substrate Non-substrate 0.8376 CYP450 2D6 substrate Non-substrate 0.7529 CYP450 3A4 substrate Substrate 0.6975 CYP450 1A2 substrate Non-inhibitor 0.8986 CYP450 2C9 inhibitor Non-inhibitor 0.9583 CYP450 2D6 inhibitor Non-inhibitor 0.8914 CYP450 2C19 inhibitor Non-inhibitor 0.9348 CYP450 3A4 inhibitor Non-inhibitor 0.8426 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.919 Ames test Non AMES toxic 0.7046 Carcinogenicity Non-carcinogens 0.9137 Biodegradation Not ready biodegradable 0.876 Rat acute toxicity 2.6607 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8134 hERG inhibition (predictor II) Non-inhibitor 0.6401
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Isoquinolines and derivatives
- Sub Class
- Benzylisoquinolines
- Direct Parent
- Benzylisoquinolines
- Alternative Parents
- Tetrahydroisoquinolines / Phenoxy compounds / Anisoles / Methoxybenzenes / Alkyl aryl ethers / Aralkylamines / Fatty acid esters / Dicarboxylic acids and derivatives / Tetraalkylammonium salts / Carboxylic acid esters show 7 more
- Substituents
- Benzylisoquinoline / Tetrahydroisoquinoline / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Fatty acid ester / Aralkylamine / Monocyclic benzene moiety show 21 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- isoquinolines (CHEBI:6958)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Drug binding
- Specific Function
- After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
- Gene Name
- CHRNA2
- Uniprot ID
- Q15822
- Uniprot Name
- Neuronal acetylcholine receptor subunit alpha-2
- Molecular Weight
- 59764.82 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Ihmsen H, Schmidt J, Schwilden H, Schmitt HJ, Muenster T: Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy. Anesthesiology. 2009 May;110(5):1016-9. doi: 10.1097/ALN.0b013e31819daf31. [PubMed:19352159]
- Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616]
- Jonsson M, Gurley D, Dabrowski M, Larsson O, Johnson EC, Eriksson LI: Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade. Anesthesiology. 2006 Sep;105(3):521-33. [PubMed:16931985]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- AntagonistPartial agonist
- General Function
- G-protein coupled acetylcholine receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM2
- Uniprot ID
- P08172
- Uniprot Name
- Muscarinic acetylcholine receptor M2
- Molecular Weight
- 51714.605 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- Receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM3
- Uniprot ID
- P20309
- Uniprot Name
- Muscarinic acetylcholine receptor M3
- Molecular Weight
- 66127.445 Da
References
- Habre W, Adamicza A, Lele E, Novak T, Sly PD, Petak F: The involvement of histaminic and muscarinic receptors in the bronchoconstriction induced by myorelaxant administration in sensitized rabbits. Anesth Analg. 2008 Dec;107(6):1899-906. doi: 10.1213/ane.0b013e318186587c. [PubMed:19020136]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Identical protein binding
- Specific Function
- Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
- Gene Name
- BCHE
- Uniprot ID
- P06276
- Uniprot Name
- Cholinesterase
- Molecular Weight
- 68417.575 Da
References
- Kao YJ, Le ND: The reversal of profound mivacurium-induced neuromuscular blockade. Can J Anaesth. 1996 Nov;43(11):1128-33. [PubMed:8922768]
Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:52